Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2023; 13(3):931-954. doi:10.7150/thno.78639 This issue Cite

Review

Targeted and responsive biomaterials in osteoarthritis

Jiadong Li1,2,3,4*, Hao Zhang1,2*, Yafei Han1,2*, Yan Hu1,2✉, Zhen Geng1,2✉, Jiacan Su1,2✉

1. Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China.
2. Organoid Research Center, Shanghai University, Shanghai, 200444, China.
3. School of Medicine, Shanghai University, Shanghai 200444, China.
4. School of Life Sciences, Shanghai University, Shanghai 200444, China.
*These authors contributed equally to this study.

✉ Corresponding authors: Yan Hu, E-mail: xjhuyanedu.cn; Zhen Geng, E-mail: nanboshan1987com; Jiacan Su, E-mail: drsujiacancom.

Citation:
Li J, Zhang H, Han Y, Hu Y, Geng Z, Su J. Targeted and responsive biomaterials in osteoarthritis. Theranostics 2023; 13(3):931-954. doi:10.7150/thno.78639. https://www.thno.org/v13p0931.htm
Other styles

File import instruction

Abstract

Graphic abstract

Osteoarthritis (OA) is a degenerative disease characterized by loss of articular cartilage and chronic inflammation, involving multiple cellular dysfunctions and tissue lesions. The non-vascular environment and dense cartilage matrix in the joints tend to block drug penetration, resulting in low drug bioavailability. There is a desire to develop safer and more effective OA therapies to meet the challenges of an aging world population in the future. Biomaterials have achieved satisfactory results in improving drug targeting, prolonging the duration of action, and achieving precision therapy. This article reviews the current basic understanding of the pathological mechanisms and clinical treatment dilemmas of OA, summarizes and discusses the advances for different kinds of targeted and responsive biomaterials in OA, seeking to provide new perspectives for the treatment of OA. Subsequently, limitations and challenges in clinical translation and biosafety are analyzed to guide the development of future therapeutic strategies for OA. As the need for precision medicine rises over time, emerging multifunctional biomaterials based on tissue targeting and controlled release will become an irreplaceable part of OA management.

Keywords: Osteoarthritis, articular cartilage, targeted biomaterial, responsive biomaterial, drug delivery

Citation styles

APA
Li, J., Zhang, H., Han, Y., Hu, Y., Geng, Z., Su, J. (2023). Targeted and responsive biomaterials in osteoarthritis. Theranostics, 13(3), 931-954. https://doi.org/10.7150/thno.78639.

ACS
Li, J.; Zhang, H.; Han, Y.; Hu, Y.; Geng, Z.; Su, J. Targeted and responsive biomaterials in osteoarthritis. Theranostics 2023, 13 (3), 931-954. DOI: 10.7150/thno.78639.

NLM
Li J, Zhang H, Han Y, Hu Y, Geng Z, Su J. Targeted and responsive biomaterials in osteoarthritis. Theranostics 2023; 13(3):931-954. doi:10.7150/thno.78639. https://www.thno.org/v13p0931.htm

CSE
Li J, Zhang H, Han Y, Hu Y, Geng Z, Su J. 2023. Targeted and responsive biomaterials in osteoarthritis. Theranostics. 13(3):931-954.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use